Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,502.78 | 20.42 | 0.27% |
| DAX 40 | 22,064.51 | 102.54 | 0.47% |
| Dow JONES (US) | 39,989.38 | 382.81 | 0.97% |
| FTSE 100 | 8,407.44 | 4.26 | 0.05% |
| HKSE | 21,909.76 | 162.86 | -0.74% |
| NASDAQ | 17,077.43 | 369.38 | 2.21% |
| Nikkei 225 | 35,039.15 | 170.52 | 0.49% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,465.35 | 89.49 | 1.66% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,297.29 | 0.93 | 0.03% |